share_log

Allarity Therapeutics | 424B5: Prospectus

Allarity Therapeutics | 424B5: Prospectus

Allarity Therapeutics | 424B5:募资说明书
美股SEC公告 ·  05/17 16:15
Moomoo AI 已提取核心信息
Allarity Therapeutics Inc. has announced an amendment to its Sales Agreement with Ascendiant Capital Markets, LLC, increasing the total amount of common stock it may offer and sell to $30,000,000. This update, detailed in a prospectus supplement filed on May 17, 2024, follows the company's public float surpassing $75 million on May 2, 2024, which lifted the previous sales limitation under General Instruction I.B.6 of Form S-3. As of the date of the prospectus supplement, Allarity Therapeutics has already sold 18,756,178 shares for gross proceeds of $22,537,915. The prospectus supplement amends the prior prospectus dated November 29, 2023, and the subsequent supplement dated March 19, 2024. Investors are cautioned that investing in Allarity's common stock involves high risk, and they should review the risk factors detailed in the March 19, 2024, prospectus supplement and other referenced documents.
Allarity Therapeutics Inc. has announced an amendment to its Sales Agreement with Ascendiant Capital Markets, LLC, increasing the total amount of common stock it may offer and sell to $30,000,000. This update, detailed in a prospectus supplement filed on May 17, 2024, follows the company's public float surpassing $75 million on May 2, 2024, which lifted the previous sales limitation under General Instruction I.B.6 of Form S-3. As of the date of the prospectus supplement, Allarity Therapeutics has already sold 18,756,178 shares for gross proceeds of $22,537,915. The prospectus supplement amends the prior prospectus dated November 29, 2023, and the subsequent supplement dated March 19, 2024. Investors are cautioned that investing in Allarity's common stock involves high risk, and they should review the risk factors detailed in the March 19, 2024, prospectus supplement and other referenced documents.
Allarity Therapeutics Inc.宣布修订其与Ascendiant Capital Markets, LLC的销售协议,将其可能发行和出售的普通股总额增加到3000万美元。2024年5月17日提交的招股说明书补充文件详细介绍了这一更新,此前该公司的公开持股量于2024年5月2日超过7,500万美元,这取消了先前根据S-3表格I.B.6号一般指令规定的销售限制。截至招股说明书补充文件发布之日,Allarity Therapeutics已经出售了18,756,178股股票,总收益为22,537,915美元。招股说明书补充文件修订了2023年11月29日的先前招股说明书以及随后于2024年3月19日发布的补充说明书。提醒投资者,投资Allarity的普通股涉及高风险,他们应查看2024年3月19日、招股说明书补充文件和其他参考文件中详述的风险因素。
Allarity Therapeutics Inc.宣布修订其与Ascendiant Capital Markets, LLC的销售协议,将其可能发行和出售的普通股总额增加到3000万美元。2024年5月17日提交的招股说明书补充文件详细介绍了这一更新,此前该公司的公开持股量于2024年5月2日超过7,500万美元,这取消了先前根据S-3表格I.B.6号一般指令规定的销售限制。截至招股说明书补充文件发布之日,Allarity Therapeutics已经出售了18,756,178股股票,总收益为22,537,915美元。招股说明书补充文件修订了2023年11月29日的先前招股说明书以及随后于2024年3月19日发布的补充说明书。提醒投资者,投资Allarity的普通股涉及高风险,他们应查看2024年3月19日、招股说明书补充文件和其他参考文件中详述的风险因素。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息